Transcode Therapeutics, Inc. earnings releases RNAZ

Transcode Therapeutics, Inc. last reported quarterly results on Apr 5, 2024, for the quarter ended Mar 31, 2024. It usually reports 5–45 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 5–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Apr 5, 2024
5 days after quarter end
—
ended Mar 31, 2024
—
—
—
Jan 16, 2024
16 days after quarter end
—
ended Dec 31, 2023
—
—
—
Nov 14, 2023
45 days after quarter end
—
ended Sep 30, 2023
—
—
—
Feb 1, 2023
32 days after quarter end
—
ended Dec 31, 2022
—
—
—
Nov 14, 2022
45 days after quarter end
—
ended Sep 30, 2022
—
—
—
Aug 15, 2022
46 days after quarter end
—
ended Jun 30, 2022
—
—
—
Apr 1, 2022
1 days after quarter end
—
ended Mar 31, 2022
—
—
—
Nov 15, 2021
46 days after quarter end
—
ended Sep 30, 2021
—
—
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
RNAZ (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
, Emerging growth company
SEC CIK
1829635

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.